PRMT5 INHIBITION RESTARTS A PRO‐APOPTOTIC PROGRAM AND CREATES VULNERABILITY TO COMBINATION TREATMENT WITH BCL‐2 INHIBITOR VENETOCLAX IN MANTLE CELL LYMPHOMA.

Details

Language :

English

ISSN :

02780232

Volume :

39

Database :

Complementary Index

Journal :

Hematological Oncology

Publication Type :

Academic Journal

Accession number :

150945347

Full Text :

https://doi.org/10.1002/hon.143_2880